T1	PROC 44 80	Estudio de fase 3, abierto y cruzado
T2	PROC 98 116	autoadministración
T3	CHEM 121 136	rozanolixizumab
T4	LIVB 145 158	participantes
T5	DISO 177 180	gMG
T6	PROC 202 227	Estudio abierto y cruzado
T7	PROC 244 262	autoadministración
T8	CHEM 267 282	rozanolixizumab
T9	LIVB 291 304	participantes
T10	DISO 323 352	miastenia gravis generalizada
T11	DISO 378 394	miastenia gravis
#1	AnnotatorNotes T11	C0026896; Myasthenia Gravis; Disease or Syndrome
T12	DISO 402 428	enfermedad autoinmunitaria
#2	AnnotatorNotes T12	C0004364; Autoimmune Diseases; Disease or Syndrome
T13	DISO 439 464	debilidad en los músculos
T14	ANAT 519 526	nervios
#3	AnnotatorNotes T14	C0027740; Nerve; Body Part, Organ, or Organ Component | C1280541; Entire nerve; Body Part, Organ, or Organ Component
T15	ANAT 533 541	músculos
#4	AnnotatorNotes T15	C0026845; Muscle Tissue; Tissue | C1305763; Skeletal and/or smooth muscle structure; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T16	DISO 567 596	Miastenia gravis generalizada
T17	LIVB 629 642	participantes
T18	PROC 672 683	diagnóstico
#5	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 699 715	Miastenia gravis
#6	AnnotatorNotes T19	C0026896; Myasthenia Gravis; Disease or Syndrome
T20	LIVB 727 739	participante
T21	PROC 804 835	autoadministración domiciliaria
T22	LIVB 858 870	participante
T23	CHEM 890 905	rozanolixizumab
T24	PROC 918 929	Tratamiento
#7	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 975 988	Peso corporal
T26	LIVB 1003 1016	participantes
T27	LIVB 1040 1047	hombres
#8	AnnotatorNotes T27	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T28	LIVB 1050 1057	mujeres
#9	AnnotatorNotes T28	C0043210; Woman; Population Group | C0242665; wife; Family Group
T29	LIVB 1089 1101	participante
T30	DISO 1124 1141	hipersensibilidad
#10	AnnotatorNotes T30	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T31	CHEM 1187 1198	medicamento
#11	AnnotatorNotes T31	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T32	CHEM 1219 1257	medicamentos anti-receptor Fc neonatal
T33	CHEM 1259 1263	FcRn
T34	LIVB 1268 1280	Participante
T35	DISO 1301 1326	infección de tuberculosis
T36	DISO 1328 1330	TB
#12	AnnotatorNotes T36	C0005586; Bipolar Disorder; Mental or Behavioral Dysfunction | C0040586; Tracheobronchitis; Disease or Syndrome | C0041296; Tuberculosis; Disease or Syndrome
T37	Spec_cue 1351 1360	riesgo de
T38	DISO 1374 1389	infección de TB
T39	Speculated 1374 1389	infección de TB
T40	DISO 1396 1429	infección de tuberculosis latente
T41	Speculated 1396 1429	infección de tuberculosis latente
T42	DISO 1431 1435	LTBI
T43	Speculated 1431 1435	LTBI
T44	DISO 1444 1487	infección por micobacterias no tuberculosas
T45	Speculated 1444 1487	infección por micobacterias no tuberculosas
T46	Date 1488 1494	actual
T47	DISO 1507 1512	NTMBI
T48	Speculated 1507 1512	NTMBI
T49	LIVB 1519 1531	participante
T50	DISO 1554 1563	infección
#13	AnnotatorNotes T50	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T51	DISO 1612 1621	infección
#14	AnnotatorNotes T51	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T52	PROC 1644 1659	hospitalización
#15	AnnotatorNotes T52	C0019993; Hospitalization; Health Care Activity
T53	PROC 1671 1682	tratamiento
#16	AnnotatorNotes T53	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T54	CHEM 1687 1699	antibióticos
#17	AnnotatorNotes T54	C0003232; Antibiotics; Antibiotic
T55	Route 1704 1719	vía intravenosa
T56	Duration 1731 1744	las 6 semanas
T57	PROC 1761 1767	visita
T58	LIVB 1781 1793	participante
T59	CHEM 1852 1867	rozanolixizumab
T60	PROC 1915 1921	retiro
T61	PROC 1924 1960	interrupción obligatoria del fármaco
T62	LIVB 1979 1991	participante
T63	CHEM 2020 2031	vacuna viva
T64	Duration 2042 2055	las 4 semanas
T65	PROC 2077 2088	tratamiento
#18	AnnotatorNotes T65	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T66	CHEM 2096 2130	vacuna de Bacillus Calmette Guérin
T67	CHEM 2132 2135	BCG
#19	AnnotatorNotes T67	C0004886; BCG Vaccine; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance | C2698319; Bacillus Calmette-Guerin Antigen; Immunologic Factor
T68	Duration 2147 2152	1 año
T69	PROC 2174 2185	tratamiento
#20	AnnotatorNotes T69	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T70	CHEM 2223 2234	vacuna viva
T71	Duration 2276 2289	las 8 semanas
T72	CHEM 2323 2338	rozanolixizumab
T73	LIVB 2341 2353	Participante
T74	DISO 2370 2379	debilidad
#21	AnnotatorNotes T74	C0424594; Frailty; Finding | C3714552; Weakness; Sign or Symptom
T75	DISO 2467 2483	miastenia gravis
#22	AnnotatorNotes T75	C0026896; Myasthenia Gravis; Disease or Syndrome
T76	ANAT 2500 2537	músculos orofaríngeos o respiratorios
T77	DISO 2555 2572	crisis miasténica
T78	DISO 2579 2585	crisis
#23	AnnotatorNotes T78	C0036572; Seizures; Sign or Symptom | C0231224; Crisis; Finding
T79	DISO 717 720	gMG
T80	PROC 2415 2454	escala de actividades de la vida diaria
T81	PROC 2456 2462	MG-ADL
T82	DISO 1868 1870	MG
T83	Observation 757 766	dispuesto
T84	Observation 783 788	capaz
T85	Result_or_Value 989 996	>=35 kg
T86	Observation 1346 1360	alto riesgo de
T87	Quantifier_or_Qualifier 1564 1570	activa
T88	Quantifier_or_Qualifier 1571 1593	clínicamente relevante
T89	Quantifier_or_Qualifier 1622 1627	grave
T90	Quantifier_or_Qualifier 1768 1775	inicial
T91	Observation 1806 1848	participó previamente en cualquier estudio
T92	Observation 1881 1898	con los criterios
T93	CONC 2307 2319	última dosis
T94	Quantifier_or_Qualifier 2380 2385	grave
T95	Result_or_Value 2401 2408	grado 3
T96	CONC 2415 2454	escala de actividades de la vida diaria
T97	CONC 2456 2462	MG-ADL
T98	Quantifier_or_Qualifier 2586 2595	inminente
T99	Patient 145 158	participantes
T100	Patient 291 304	participantes
T101	Patient 629 642	participantes
T102	Patient 727 739	participante
T103	Patient 858 870	participante
T104	Patient 1003 1016	participantes
T105	Patient 1040 1047	hombres
T106	Patient 1050 1057	mujeres
T107	Patient 1089 1101	participante
T108	History_of 1124 1141	hipersensibilidad
T109	Patient 1249 1257	neonatal
T110	Patient 1268 1280	Participante
T111	History_of 1301 1326	infección de tuberculosis
T112	History_of 1328 1330	TB
T113	History_of 1406 1421	de tuberculosis
T114	History_of 1444 1487	infección por micobacterias no tuberculosas
T115	History_of 1507 1512	NTMBI
T116	Patient 1519 1531	participante
T117	History_of 1612 1621	infección
T118	Patient 1781 1793	participante
T119	History_of 1852 1867	rozanolixizumab
T120	Patient 1979 1991	participante
T121	History_of 2020 2031	vacuna viva
T122	History_of 2096 2102	vacuna
T123	History_of 2106 2130	Bacillus Calmette Guérin
T124	History_of 2132 2135	BCG
T125	Future 2223 2234	vacuna viva
T126	History_of 2323 2338	rozanolixizumab
T127	Patient 2341 2353	Participante
T128	Future 2555 2561	crisis
T129	Future 2579 2585	crisis
